Patents Examined by Agnieszka Boesen
-
Patent number: 12042537Abstract: The present disclosure provides methods, uses and compositions and kits for use in inducing an antibody immune response in a human subject. The methods and uses involve administering parenterally a low dose volume of a composition comprising an antigen comprising a B-cell epitope, an amphipathic compound, and a hydrophobic carrier, wherein the low dose volume of the composition is less than 100 ?l and induces an antibody immune response to the B-cell epitope in the human subject.Type: GrantFiled: June 30, 2022Date of Patent: July 23, 2024Assignee: BioVaxys Inc.Inventors: Marc Mansour, Frederic Ors, Marianne Stanford, Leeladhar Sammatur, Rajkannan Rajagopalan, Lisa Diana MacDonald
-
Patent number: 12037381Abstract: The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and potently neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The invention also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.Type: GrantFiled: July 18, 2022Date of Patent: July 16, 2024Assignee: Humabs BioMed SAInventor: Davide Corti
-
Patent number: 12036272Abstract: The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise antigens, such as peptide-MHC (pMHC) class I molecules, and specific combinations of cytokines and co-stimulatory molecules to allow effective expansion and functional stimulation of specific T cells.Type: GrantFiled: December 9, 2022Date of Patent: July 16, 2024Assignee: Danmarks Tekniske UniversitetInventors: Sine Reker Hadrup, Vibeke Mindahl Rafa, Søren Nyboe Jakobsen
-
Patent number: 12025622Abstract: Disclosed herein are methods and compositions for identifying and/or treating subjects having or likely to have amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). Antibodies specific for one or more di-amino acid repeat-containing proteins are also provided herein.Type: GrantFiled: May 17, 2021Date of Patent: July 2, 2024Assignee: University of Florida Research Foundation, IncorporatedInventors: Laura Ranum, Tao Zu
-
Patent number: 12018049Abstract: Provided herein are agents, compositions, and methods useful for animal health, e.g., for altering the level, activity, or metabolism of one or more microorganisms resident in a host insect (e.g., arthropod, e.g., insect, e.g., pathogen vector), the alteration resulting in a decrease in the fitness of the host. The invention features a composition that includes an agent (e.g., phage, peptide, small molecule, antibiotic, or combinations thereof) that can alter the host's microbiota in a manner that is detrimental to the host. By disrupting microbial levels, microbial activity, microbial metabolism, or microbial diversity, the agents described herein may be used to decrease the fitness of a variety of insects that carry vector-borne pathogens that cause disease in animals.Type: GrantFiled: December 2, 2020Date of Patent: June 25, 2024Assignee: Flagship Pioneering Innovations V, Inc.Inventors: Ignacio Martinez, Zachary Garo Armen, Barry Andrew Martin, Maier Steve Avendano Amado
-
Patent number: 12018290Abstract: Methods for continuously inactivating a virus during manufacture of a protein are provided. Steps include (1) combining, at a single predetermined volumetric ratio, a composition including the protein, and a composition including a virus-inactivation reagent, to obtain a treatment composition having a predetermined property for inactivation of a virus; (2) transferring the treatment composition to a treatment vessel; (3) incubating the treatment composition in the treatment vessel at predetermined conditions; and (4) subjecting the treatment composition to a post-treatment processing operation. The single predetermined volumetric ratio has been selected to ensure that the predetermined property of the treatment composition is maintained across a range of concentrations predicted for the protein in the composition including the protein.Type: GrantFiled: June 30, 2022Date of Patent: June 25, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Marcus Andre Fiadeiro, Jonathan Coffman, Robert Lee Fahrner, Jill Ann Kublbeck, Raquel Orozco, Jeffrey Richard Salm
-
Patent number: 12018291Abstract: The present invention provides compositions of CD 180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.Type: GrantFiled: December 9, 2022Date of Patent: June 25, 2024Assignee: UNIVERSITY OF WASHINGTONInventors: Edward Clark, Jay Wesley Chaplin
-
Patent number: 12005112Abstract: Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of a mixture of immunogenic vaccine molecules comprising components for targeting the dimeric vaccine molecules to antigen-presenting cells and components for eliciting an immunogenic response, wherein the components for eliciting an immunogenic response preferably comprise at least three variants of an immunogenic protein, such as variants of immunogenic proteins obtained from three or more different strains of a pathogenic organism.Type: GrantFiled: September 7, 2018Date of Patent: June 11, 2024Assignee: University of OsloInventors: Gunnveig Grødeland, Bjarne Bogen, Ane Marie Anderson
-
Patent number: 11993634Abstract: The present disclosure discloses a recombinant varicella-zoster virus (VZV) vaccine, including a fusion protein formed by an amino acid sequence of an extracellular domain of a recombinant glycoprotein gE of a live attenuated VZV strain (OKA strain) gene and an Fc fragment of human immunoglobulin. The present disclosure further provides preparation and use of the fusion protein, a corresponding recombinant gene, a eukaryotic expression vector, etc. The fusion protein of the present disclosure has prominent immunogenicity and can induce the high-level expression of neutralizing antibodies in serum.Type: GrantFiled: May 14, 2020Date of Patent: May 28, 2024Assignee: BEIJING LUZHU BIOTECHNOLOGY CO., LTD.Inventors: Jian Kong, Pei Hong Jiang, Ling Peng, Shuai Yang, Leitao Xu, Kun Zhang
-
Patent number: 11987610Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.Type: GrantFiled: November 10, 2023Date of Patent: May 21, 2024Assignee: Cue Biopharma, Inc.Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
-
Patent number: 11980661Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: GrantFiled: December 22, 2021Date of Patent: May 14, 2024Assignee: FluGen, Inc.Inventors: Pamuk Bilsel, Yasuko Hatta
-
Patent number: 11969466Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.Type: GrantFiled: May 8, 2023Date of Patent: April 30, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
-
Patent number: 11964006Abstract: Disclosed are vaccine compositions comprising a VLP comprising two or more EBV envelope glycoproteins and one or more T cell antigens and methods of preventing or treating EBV infections using the vaccine compositions. Also disclosed is an expression system or a single expression vector for co-expressing two or more EBV envelope glycoproteins simultaneously to generate a VLP vaccine. The expression system may include a single vector inserted with two or more nucleic acid sequences that encode two or more EBV envelope glycoproteins linked by one or more linking sequences such that the EBV envelope glycoproteins are co-expressed simultaneously.Type: GrantFiled: September 16, 2018Date of Patent: April 23, 2024Assignee: CITY OF HOPEInventors: Javier Gordon Ogembo, Lorraine Zvichapera Mutsvunguma, Felix Wussow
-
Patent number: 11965000Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.Type: GrantFiled: September 7, 2023Date of Patent: April 23, 2024Assignee: CureVac SEInventors: Thomas Kramps, Margit Schnee, Daniel Voss, Benjamin Petsch
-
Patent number: 11932681Abstract: The present invention relates to anti-HBsAg antibodies, antibody fragments, and their uses for the prevention and treatment of hepatitis B virus infection and associated diseases.Type: GrantFiled: May 30, 2019Date of Patent: March 19, 2024Assignee: Novartis AGInventors: Stefan Ewert, Meghan Marie Holdorf, Elisabetta Traggiai
-
Patent number: 11932879Abstract: This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent.Type: GrantFiled: June 23, 2022Date of Patent: March 19, 2024Assignee: Mayo Foundation for Medical Education and ResearchInventors: Mark J. Federspiel, Arun Ammayappan, Gennett Pike, Stephen James Russell
-
Patent number: 11905320Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.Type: GrantFiled: May 26, 2023Date of Patent: February 20, 2024Assignee: Cue Biopharma, Inc.Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
-
Patent number: 11896662Abstract: Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.Type: GrantFiled: November 24, 2021Date of Patent: February 13, 2024Assignee: Novavax, Inc.Inventors: Sarathi Boddapati, Anushree Herwadkar, Jason Wong, Yen-Huei Lin, Gale Smith, Jing-Hui Tian
-
Patent number: 11865080Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.Type: GrantFiled: December 13, 2022Date of Patent: January 9, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Patent number: 11866463Abstract: The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition. The invention also relates to antibodies to composite antigens of the invention and to methods of administering vaccines comprising antigens or vaccines of antibodies for treating and/or preventing an infection.Type: GrantFiled: January 29, 2021Date of Patent: January 9, 2024Assignee: Longhorn Vaccines and Diagnostics, LLCInventors: Luke T. Daum, Gerald W. Fischer, Clara J. Sei